Anti-osteoporosis Medication Use in a High Fracture-Risk Population: Contemporary Trends in Australian Residential Aged Care Facilities
Osteoporotic fractures impose substantial morbidity and mortality among older adults. Undertreatment is an ongoing concern; treatment rates declined following reports of adverse effects of guideline-recommended bisphosphonates, but new antiresorptives have since become available. Our goal was to ide...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2019-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_8374aa18a95e4dc99458ace77ba3ee9d | ||
042 | |a dc | ||
100 | 1 | 0 | |a Kimberly E Lind |e author |
700 | 1 | 0 | |a Mikaela L Jorgensen |e author |
700 | 1 | 0 | |a Leonard C Gray |e author |
700 | 1 | 0 | |a Andrew Georgiou |e author |
700 | 1 | 0 | |a Johanna I Westbrook |e author |
245 | 0 | 0 | |a Anti-osteoporosis Medication Use in a High Fracture-Risk Population: Contemporary Trends in Australian Residential Aged Care Facilities |
260 | |b SAGE Publishing, |c 2019-05-01T00:00:00Z. | ||
500 | |a 1178-6329 | ||
500 | |a 10.1177/1178632919852111 | ||
520 | |a Osteoporotic fractures impose substantial morbidity and mortality among older adults. Undertreatment is an ongoing concern; treatment rates declined following reports of adverse effects of guideline-recommended bisphosphonates, but new antiresorptives have since become available. Our goal was to identify contemporary trends in osteoporosis treatment guideline adherence in a high fracture-risk population. We conducted a secondary data analysis using electronic health record data of adults aged ⩾65 years from 68 residential aged care facilities in Australia during 2014-2017 (n = 9094). Using medication administration data, we identified antiresorptive (bisphosphonates and denosumab) and vitamin D supplement use among residents with osteoporosis. Regression was used to evaluate temporal trends, and resident and facility characteristics associated with antiresorptive use and vitamin D use. In 2014, 34% of women and 42% of men with osteoporosis used antiresorptives; this decreased 8 percentage points by 2017. Antiresorptive use was higher among those with a history of fracture and lower in the last year of life. Denosumab use increased but did not substitute for the continued decline in bisphosphonate use. Vitamin D was consistently used by more than 60% of residents and was higher among those with fracture history. Greater attention to the treatment of osteoporosis treatment rates among this high fracture-risk population is warranted. | ||
546 | |a EN | ||
690 | |a Medicine (General) | ||
690 | |a R5-920 | ||
690 | |a Public aspects of medicine | ||
690 | |a RA1-1270 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Health Services Insights, Vol 12 (2019) | |
787 | 0 | |n https://doi.org/10.1177/1178632919852111 | |
787 | 0 | |n https://doaj.org/toc/1178-6329 | |
856 | 4 | 1 | |u https://doaj.org/article/8374aa18a95e4dc99458ace77ba3ee9d |z Connect to this object online. |